 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ||| ABC008 / Abcuro
Enrollment change, Trial completion date, Trial primary completion date: ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (clinicaltrials.gov) - Sep 26, 2023
P1/2, N=30, Recruiting, Sponsor: Abcuro, Inc.
N=15 --> 30 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||| ABC008 / Abcuro
Enrollment open: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (clinicaltrials.gov) - Jun 5, 2023
P2/3, N=231, Recruiting, Sponsor: Abcuro, Inc.
N=15 --> 30 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Active, not recruiting --> Recruiting
- ||||| ABC008 / Abcuro
Enrollment closed: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (clinicaltrials.gov) - May 31, 2023
P2/3, N=231, Active, not recruiting, Sponsor: Abcuro, Inc.
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| ABC008 / Abcuro
Enrollment open: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (clinicaltrials.gov) - Mar 10, 2023
P2/3, N=231, Recruiting, Sponsor: Abcuro, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||||||| ABC008 / Abcuro
New P2/3 trial: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis (clinicaltrials.gov) - Feb 10, 2023
P2/3, N=231, Not yet recruiting, Sponsor: Abcuro, Inc.
- | ABC008 / Abcuro
Trial completion date, Trial primary completion date: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (clinicaltrials.gov) - Jan 4, 2023
P1, N=30, Recruiting, Sponsor: Abcuro, Inc.
Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> May 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
- ABC008 / Abcuro, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas (ENMCC - 391-392) - Nov 4, 2022 - Abstract #ASH2022ASH_5344;
Selective depletion of tumor cells with an anti-KLRG1 depleting mAb in specific subtypes of TCLs, T-LGLL, and CLPD-NK is effective in vitro and in vivo, and its combination with Duv has marked activity in an aggressive PTCL-NOS xenograft model. A multicenter phase I/II trial of the KLRG1 depleting antibody ABC008 (Abcuro) in patients with R/R T-LGLL has been initiated.
- || ABC008 / Abcuro
New P1/2 trial: ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) (clinicaltrials.gov) - Sep 8, 2022
P1/2, N=15, Recruiting, Sponsor: Abcuro, Inc.
- | ABC008 / Abcuro
Trial completion date, Trial primary completion date: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (clinicaltrials.gov) - Jan 20, 2022
P1, N=27, Recruiting, Sponsor: Abcuro, Inc.
A multicenter phase I/II trial of the KLRG1 depleting antibody ABC008 (Abcuro) in patients with R/R T-LGLL has been initiated. Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023
- || ABC008 / Abcuro
Enrollment open: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (clinicaltrials.gov) - Jul 1, 2021
P1, N=27, Recruiting, Sponsor: Abcuro, Inc.
Trial completion date: Dec 2021 --> Dec 2023 | Trial primary completion date: Dec 2021 --> Dec 2023 Not yet recruiting --> Recruiting
- | ABC008 / Abcuro
Enrollment change: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (clinicaltrials.gov) - Dec 25, 2020
P1, N=27, Not yet recruiting, Sponsor: Abcuro, Inc.
Not yet recruiting --> Recruiting N=39 --> 27
- | ABC008 / Abcuro
New P1 trial: A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) (clinicaltrials.gov) - Dec 8, 2020
P1, N=39, Not yet recruiting, Sponsor: Abcuro, Inc.